Berenberg raises target for Redcare Pharmacy stock to EUR 102.00

Published on 10/26/2026 at 16:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due October 29, 2026. Redcare Pharmacy stock costs EUR 78.23 on October 26, 2026, plus 0.42 percent versus the Xetra close.

Analyst target and reporting date

Berenberg raised its Redcare Pharmacy target from EUR 94.00 to EUR 102.00 on October 7, 2026.
Redcare Pharmacy will publish its third-quarter 2026 results on October 29, 2026.
Redcare Pharmacy stock costs EUR 78.23 at Lang & Schwarz on October 26, 2026 at 4:15 p.m. CET, plus 0.42 percent versus the Xetra close of October 23, 2026, 5.23 percent below the 52-week high.
Second-quarter 2026 revenue reached EUR 853.5 million, up 20.00 percent year over year.

Redcare Pharmacy, NL0012044747, Illustration mit AI erstellt.

Redcare Pharmacy (ISIN NL0012044747) is priced at EUR 78.23 at Lang & Schwarz on October 26, 2026 at 4:15 p.m. CET, up EUR 0.33 or 0.42 percent versus the Xetra close of October 23, 2026. Berenberg lifted its price target from EUR 94.00 to EUR 102.00 while retaining its Buy rating, according to onvista on October 7, 2026. The new target lies 30.37 percent above the Lang & Schwarz price.

Revenue growth meets the next date

Redcare Pharmacy's latest reported quarter delivered EUR 853.5 million in revenue in the second quarter of 2026, up 20.00 percent from the second quarter of 2025. Net income reached EUR 4.70 million, down 50.00 percent year over year, while earnings per share fell to EUR 0.23 from EUR 0.46, according to Simply Wall St on October 15, 2026.

The next scheduled corporate event is the third-quarter interim statement on October 29, 2026. The company also lists a Baader Bank investor meeting for November 2, 2026, on its investor-relations page. The reporting date matters because the second-quarter revenue gain came with a lower profit base.

Stock stays below the yearly high

Redcare Pharmacy stock is EUR 4.32 below its 52-week high of EUR 82.55 and EUR 48.03 above its 52-week low of EUR 30.20. The market capitalization is EUR 1.6 billion, and trading volume stood at 39,009 shares in the latest Xetra quote. The price therefore remains below the yearly peak despite the recent analyst target increases.

Guidance sets the valuation frame

Redcare Pharmacy raised its full-year 2026 total revenue growth guidance to 16.00 percent to 18.00 percent from 15.00 percent to 17.00 percent on September 28, 2026. Its German prescription revenue target rose to EUR 730 million to EUR 760 million from EUR 680 million to EUR 720 million, while the adjusted EBITDA margin target stayed at 2.50 percent to 3.00 percent, according to the company's Redcare Pharmacy release dated September 28, 2026.

The combination of a higher target price and the October 29 reporting date leaves the next result as the clearest numerical test of the current valuation. Berenberg's EUR 102.00 target is above the current euro price, while the stock remains 5.23 percent below its 52-week high.

Price and investor dates

Redcare Pharmacy reported EUR 853.5 million of second-quarter revenue and EUR 4.70 million of net income. The company will publish third-quarter figures on October 29, 2026, followed by a Baader Bank investor meeting on November 2, 2026.

Redcare Pharmacy was trading at EUR 78.23 at Lang & Schwarz on October 26, 2026 at 4:15 p.m. CET, plus 0.42 percent versus the Xetra close of EUR 77.90 on October 23, 2026. The further course of trading is shown by the continuously updated real-time quote of Redcare Pharmacy stock.